Evidence map›Paper›PMID 38638799›Full record

ArticleThe World Allergy Organization journal2024

HLA-DRB1 is associated with cefaclor-induced immediate hypersensitivity.

So-Young Park, So Young Park, Sujin Seo, Hyouk-Soo Kwon, Seung-Hyun Kim, Sae-Hoon Kim, Hye-Kyung Park, Yoon-Seok Chang, Cheol-Woo Kim, Byung Jae Lee and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

So-Young ParkDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
So Young ParkDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sujin SeoDepartment of Public Health Science, Seoul National University, Seoul, South Korea.
Hyouk-Soo KwonDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Seung-Hyun KimDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.
Sae-Hoon KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Hye-Kyung ParkDepartment of Internal Medicine, School of Medicine, Busan National University, Busan, South Korea.
Yoon-Seok ChangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Cheol-Woo KimDepartment of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
Byung Jae LeeDivision of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hae-Sim ParkDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.
You Sook ChoDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Heung-Bum OhDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
David A OstrovDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, USA.
Sungho WonDepartment of Public Health Science, Seoul National University, Seoul, South Korea.
Tae Bum KimDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ulsan College · KRSeoul National University Bundang Hospital · KRBusan National University of Education · KRSeoul National University · KRInha University · KRSamsung Medical Center · KRUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Drug-induced hypersensitivity such as anaphylaxis is an important cause of drug-related morbidity and mortality. Cefaclor is a leading cause of drug induced type I hypersensitivity in Korea, but little is yet known about genetic biomarkers to predict this hypersensitivity reaction. We aimed to evaluate the possible involvement of genes in cefaclor induced type I hypersensitivity. Methods: Whole exome sequencing (WES) and HLA genotyping were performed in 43 patients with cefaclor induced type I hypersensitivity. In addition, homology modeling was performed to identify the binding forms of cefaclor to HLA site. Results: Anaphylaxis was the most common phenotype of cefaclor hypersensitivity (90.69%). WES results show that rs62242177 and rs62242178 located in LIMD1 region were genome-wide significant at the 5 × 10 Conclusion: LIMD1, HLA-DRB1∗04:03 and HLA-DRB1∗14:54 may affect susceptibility to cefaclor induced type I hypersensitivity. Further confirmative studies with a larger patient population should be performed to ascertain the role of HLA-DRB1 and LIMD1 in the development of cefaclor induced hypersensitivity.

Indexed as

CefaclorCephalosporinDrug hypersensitivityImmediate hypersensitivityWhole exome sequencing

Identifiers

PMID38638799
PMCPMC11021981
OpenAlexW4394789147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.